Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE Here, we retrospectively studied 595 Chinese CLL patients to determine the best cutoff value for IGHV in Chinese CLL population. 31849198

2020

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE Deletion 11q22 and IGHV status predict PFS in previously untreated CLL patients. 31054420

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE CLL cases can be divided in two subgroups with different clinical course based on the mutational status of the immunoglobulin heavy variable (IGHV) genes: mutated CLL (M-CLL) and unmutated CLL (U-CLL). 31108207

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE Herein, we demonstrate that the mithralog EC-7072 displays high <i>ex vivo</i> cytotoxic activity against leukemia cells from CLL patients independently from high-risk prognostic markers and IGHV mutational status. 31681329

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE Ibrutinib is active for patients with chronic lymphocytic leukaemia irrespective of IGHV mutation status but requires continuous treatment. 31208944

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE The abnormal expression of miRNAs may play critical roles in the occurrence, development and prognosis of chronic lymphocytic leukemia (CLL), with potential ethnic differences being involved. p53 and immunoglobulin heavy chain variable region gene (IGVH) mutations were monitored and miRNA profile screening of CD19 <sup>+</sup> cells from Uygur CLL patients was performed, analyzed by miRNA arrays and verified using real-time PCR. 31425738

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE Mutated IGHV was detected in 71·2% of Taiwanese CLL and IGHV3-23 was the most frequently used gene. 31230372

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE However, the question remains of how to treat treatment-naive patients with IGHV-unmutated chronic lymphocytic leukaemia. 31582354

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE Here, we used a quantitative label-free proteomic technique to ascertain differences in the B-cell proteome from healthy donors and CLL patients with either mutated (M-CLL) or unmutated (UM-CLL) IGHV to identify new prognostic markers. 30656643

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study. 31582540

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE The n-CLL, i-CLL, and m-CLL signatures were found in 80% (n = 245/305), 17% (53/305), and 2% (7/305) of IGHV-unmutated (IGHV-U) cases, respectively, and in 9%, (19/216), 50% (108/216), and 41% (89/216) of IGHV-M cases, respectively. 31434681

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE The different types of drug resistance encountered in chronic lymphocytic leukemia (CLL) cannot be fully accounted for by the 17p deletion (and/or TP53 mutation), a complex karyotype (CK), immunoglobulin heavy-chain variable region genes (IGHV) status and gene mutations. 31066214

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE In this study, using ChIP-sequencing, we identified EZH2 and H3K27me3 target genes in two prognostic subgroups of CLL with distinct prognosis and outcome, i.e., cases with unmutated (U-CLL, n = 6) or mutated IGHV genes (M-CLL, n = 6). 31216925

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE In addition, we demonstrate that relative increase of SETA to SETB mRNA can discriminate patients with a more aggressive disease course within the otherwise favourable CLL risk classifications of IGHV mutated and favourable hierarchical fluorescence in situ hybridisation groups. 30443898

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE We here describe a patient affected by CLL with a mutated IGHV status, showing a balanced t(1;3)(q23.1;q21.3) translocation and a der(18)t(1;18)(q24.2;p11.32), accompanying the recurrent 13q14 heterozygous deletion in all analyzed cells at onset. 30877410

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE Most important markers in chronic lymphocytic leukemia (CLL) are TP53 abnormalities, including mutations and deletions, and the mutational status of immunoglobulin heavy chain (IGHV) genes. 31371221

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE Similarly, the immunoglobulin heavy chain variable region repertoire was distinct from those reported in CLL or MZL. 31590326

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE We herein suggest that the combined assessment of the IGHV mutational status and CK subtypes refines the prognostication of CLL, allowing to identify M-IGHV patients without any CK subtypes who are characterised by an indolent disease and excellent outcome after chemoimmunotherapy. 31209327

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE Patients with mutated IGHV CLL more often had mutations in KLHL6 (P = 0·001) and MYD88 (P < 0·001). 30924136

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE Finally, in certain instances, as in the case of chronic lymphocytic leukemia (CLL), the clonotypic IG sequence and, more specifically, the load of somatic hypermutations within the rearranged IG heavy variable (IGHV) gene, holds prognostic and potentially predictive value. 30350197

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 AlteredExpression BEFREE Certain genomic features, such as del(11q), expression of unmutated immunoglobulin heavy-chain variable region (IGHV) gene, or complex karyotype, predict poorer outcomes to chemotherapy in patients with chronic lymphocytic leukemia (CLL). 31447270

2019

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE These agents lead to improved outcomes in CLL, even among patients with high-risk features, such as del17p13 or TP53 mutation and unmutated immunoglobulin heavy chain (IGHV) genes. 30283014

2018

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE Both CLL and MCL include 2 major molecular subtypes that seem to derive from antigen-experienced CD5<sup>+</sup> B cells that retain a naive or memory-like epigenetic signature and carry a variable load of immunoglobulin heavy-chain variable region somatic mutations from truly unmutated to highly mutated, respectively. 29666114

2018

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE In contrast, CLL cell resistance to CDC predominates in IGHV unmutated patients and was related to an important α2-6 sialyl transferase activity, which in turn increases cell surface α2-6 hypersialylation. 30167081

2018

Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE Currently, a cut-off of 2% deviation or 98% sequence identity to germline in IGHV sequence is routinely used to dichotomize CLL patients into mutated and unmutated groups. 29164608

2018